Cbl (G694) polyclonal Antibody | BS1519

Cbl (G694) polyclonal Antibody | BS1519 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC IF

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200 IF: 1:50~1:200

Background: Cbl (also designated the c-Cbl proto-oncogene, E3 ubiquitin-protein ligase CBL,Casitas B-lineage lymphoma proto-oncogene and RING finger protein 55) has been identified as the cellular homolog of the v-Cbl oncogene isolated from an NFS/N mouse that developed a pre-B cell lymphoma following infection with the replication-competent Cas Br-M murine leukemic virus. c-Cbl is expressed at relatively high levels in a wide range of hematopoietic tumor cell lines as well as in normal tissues such as thymus and testis. The c-Cbl gene product has been identified as a cytoplasmic protein with apparent DNA binding and dimerization domains characteristic of transcription factors. A single c-Cbl locus termed CBL2 has been mapped to human chromosome 11q23. This region of chromosome 11 is involved in translocations and deletions in a broad range of leukemias; c-Cbl has been found to be translocated from chromosome 11 in leukemias with either t (4;11) or t (11;14) abnormalities.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: CBL (G694) polyclonal Antibody detects endogenous levels of CBL protein.

Molecular Weight: ~ 100, 120kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: E3 ubiquitin-protein ligase CBL; Casitas B-lineage lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL; CBL; CBL2; RNF55

Immunogen: Synthetic peptide, corresponding to amino acids 665-710 of Human Cbl.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: